Article
Oncology
Yiru Kong, Deng Shuangshuang, Xiaohua Liang, Xinli Zhou
Summary: This study elucidated the role and regulatory mechanism of RPS9 in non-small cell lung cancer (NSCLC), demonstrating that knockdown of RPS9 inhibits the progression of NSCLC via the inactivation of Stat3 and Erk signaling pathways.
Article
Medicine, Research & Experimental
Qiyao Zheng, Hui Dong, Jianshan Mo, Yi Zhang, Jie Huang, Shumin Ouyang, Shuo Shi, Kai Zhu, Xinming Qu, Wenhao Hu, Peiqing Liu, Yuanxiang Wang, Xiaolei Zhang
Summary: Constitutive activation of STAT3 is common in NSCLC and plays a crucial role in cancer progression and acquired resistance to targeted therapies. W2014-S, a novel STAT3 inhibitor, demonstrated significant anti-tumor activities by disrupting STAT3 signaling and sensitizing resistant NSCLC cells to EGFR-TKIs in vitro and in vivo. Combining W2014-S with gefitinib could be a promising strategy to overcome EGFR-TKIs acquired resistance in NSCLC patients.
Article
Pharmacology & Pharmacy
Yi Han, Jianquan Shi, Ziwei Xu, Yushan Zhang, Xiaoqing Cao, Jianhua Yu, Jie Li, Shaofa Xu
Summary: This study identified Solamargine as a potential sensitizer for DDP resistance in lung cancer. Mechanistically, Solamargine induced cell cycle arrest and apoptosis in DDP-resistant lung cancer cell lines by inhibiting the hedgehog pathway through direct binding to the SMO protein. Furthermore, Solamargine and DDP showed a synergistic effect in inhibiting DDP-resistant lung cancer cells.
FRONTIERS IN PHARMACOLOGY
(2022)
Editorial Material
Oncology
Kostas A. A. Papavassiliou, Georgios Marinos, Athanasios G. G. Papavassiliou
Summary: Signal transducer and activator of transcription 3 (STAT3) plays a critical role in the development and progression of non-small cell lung cancer (NSCLC) tumors. Several reports suggest that STAT3 is involved in immunosuppression and the promotion of resistance to immune checkpoint inhibitors. In this review, we discuss the potential therapeutic strategy of combining STAT3 inhibition with immune checkpoint inhibitors to overcome drug resistance and enhance their efficacy in NSCLC.
Article
Oncology
Francesca Ricci, Alessandro Corbelli, Roberta Affatato, Rosaria Chila, Michela Chiappa, Laura Brunelli, Robert Fruscio, Roberta Pastorelli, Fabio Fiordaliso, Giovanna Damia
Summary: Our study found that acquisition of DDP resistance is associated with morphological alterations in mitochondria, despite the lack of dysregulation in the studied genes/proteins that could explain the observed differences.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Cell Biology
Zhen-Yuan Zheng, Man-Yu Chu, Wan Lin, Ya-Qi Zheng, Xiu-E Xu, Yang Chen, Lian-Di Liao, Zhi-Yong Wu, Shao-Hong Wang, En-Min Li, Li-Yan Xu
Summary: In esophageal squamous cell carcinoma (ESCC), the MAPK signaling pathway is highly activated and associated with poor prognosis. Inhibiting MAPK leads to rapid activation of the STAT3 pathway. Combination therapy targeting both MAPK and STAT3 may be an effective strategy for ESCC treatment.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Simona Laurino, Mariarita Brancaccio, Tiziana Angrisano, Giovanni Calice, Sabino Russi, Pellegrino Mazzone, Giuseppina Di Paola, Michele Aieta, Vitina Grieco, Gabriella Bianchino, Geppino Falco, Tiziana Notarangelo
Summary: Gastric cancer, a leading cause of death globally, is difficult to treat with chemotherapy due to multidrug resistance. This study investigated the role of STAT3 in gastric cancer drug efficiency through gene expression analysis. The study found that gastric cancer cells become resistant to chemotherapy by activating alternative signaling pathways. However, inhibiting IL-6/STAT3 in combination with cisplatin treatment prevented STAT3 activation and increased lethality compared to single-agent treatment. This suggests that IL-6/STAT3 axis blockage may be a strategy to overcome resistance.
Article
Medicine, Research & Experimental
Dongliang Wang, Chaoshuai Zhao, Fei Xu, Aimi Zhang, Mingming Jin, Kunchi Zhang, Liu Liu, Qian Hua, Jian Zhao, Jianjun Liu, Hao Yang, Gang Huang
Summary: Hypoxia exacerbates cisplatin resistance in NSCLC cells by increasing the expression of PKM2 in exosomes secreted by hypoxic cisplatin-resistance cells. Exosomal PKM2 transmits cisplatin resistance to sensitive NSCLC cells by promoting glycolysis and inhibiting apoptosis. Additionally, exosomal PKM2 remodels CAFs to create an acidic microenvironment that promotes NSCLC cell proliferation and cisplatin resistance.
Article
Chemistry, Medicinal
Xiaoping Song, Lina Wang, Wei Tang, Luyao Yuan, Qingchao Liu, Jing Li, Daidi Fan
Summary: The combination of Selumetinib and Gefitinib enhances the sensitivity of non-small cell lung cancer to Gefitinib by regulating the MIG6/STAT3 pathway. Animal experiments demonstrate that the combined treatment of Selumetinib and Gefitinib effectively promotes the sensitivity of lung cancer to Gefitinib.
ARCHIVES OF PHARMACAL RESEARCH
(2023)
Article
Chemistry, Physical
Minxian Li, Mei Jiang, Mengting Chen, Lilusi Ma, Xiaocui Fang, Yanlian Yang, Chen Wang
Summary: Cell membrane-engineered nano-delivery systems have shown potential in improving drug bioavailability and reversing drug resistance in cancer therapy. In this study, a nano-liposome called cLCE was developed, which consists of a hybrid of cisplatin-resistant A549 cancer cell membrane and phospholipids, for co-delivery of cisplatin and EZH2-targeting peptide EIP103. The formulated nano-liposome demonstrated efficient inhibition of cancer cell invasion and metastasis, as well as reversal of cisplatin resistance both in vitro and in vivo.
Article
Pharmacology & Pharmacy
Bingjie Han, Yuanyuan Sun, Xiaofen Zhang, Ping Yue, Meiling Tian, Dan Yan, Fanxiang Yin, Bo Qin, Yi Zhao
Summary: Cisplatin resistance remains a major obstacle in the treatment of non-small cell lung cancer (NSCLC). This study reveals that downregulation of amino acids is associated with cisplatin resistance in NSCLC cells. Exogenous supplementation of proline enhances the sensitivity of NSCLC cells to cisplatin by inhibiting cell viability and tumor growth. The combination of proline and cisplatin also suppresses ATP production by disrupting the TCA cycle and oxidative phosphorylation. The inhibition of PLK1 in cisplatin-resistant cells leads to cell cycle arrest through transcriptional inhibition mediated by the FOXO3A-FOXM1 axis. This study suggests that exogenous proline and PLK1 may serve as potential therapeutic targets for overcoming cisplatin resistance in NSCLC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Ming Cheng, Hongyi Cao, Peifeng Yao, Jingqian Guan, Peihong Wu, Hairu Ji, Siyu Jiang, Yinan Yuan, Lin Fu, Qianqian Zheng, Qingchang Li
Summary: In non-small cell lung cancer (NSCLC), overexpression of PHF23 is associated with shorter survival times and poor response to chemotherapy. The overexpression of PHF23 promotes cell proliferation, migration, and sensitizes NSCLC cells to chemotherapy drugs by promoting DNA damage repair. These findings suggest that PHF23 plays a critical role in the development and progression of NSCLC and may serve as a therapeutic target.
CELL DEATH & DISEASE
(2023)
Article
Biochemistry & Molecular Biology
Zhenzhen Pan, Kai Wang, Xiniao Wang, Zhirong Jia, Yuqi Yang, Yalei Duan, Lianzhan Huang, Zhuo-Xun Wu, Jian-ye Zhang, Xuansheng Ding
Summary: This study reveals a common molecular mechanism underlying EGFR-TKIs resistance in non-small cell lung cancer, involving cholesterol accumulation, EGFR/Src/Erk/SP1 axis-mediated ERR alpha re-expression and subsequent cell proliferation. Lowering cholesterol levels and downregulating ERR alpha can overcome resistance to gefitinib and osimertinib.
Article
Oncology
Hong-Wei Lv, Wen-Qun Xing, Yu-Feng Ba, Hao-Miao Li, Hao-Ran Wang, Yin Li
Summary: SMYD3 is highly expressed in non-small cell lung cancer (NSCLC) tissues or cells, and correlates with higher TNM stages and resistance to cisplatin treatment, leading to shorter overall survival. Its promotion of cisplatin resistance requires co-regulator ANKHD1, with CDK2 identified as a downstream effector.
TRANSLATIONAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Linjuan Huang, Jing Zhang, Youling Deng, Hao Wang, Piao Zhao, Guozhi Zhao, Wei Zeng, Yonghui Wang, Connie Chen, William Wagstaff, Rex C. Haydon, Russell R. Reid, Tong-Chuan He, Le Shen, Hue H. Luu, Ling Zhao
Summary: Ovarian cancer is a highly lethal malignancy, often diagnosed at advanced stages due to the lack of early diagnosis methods. The standard treatment includes surgery and chemotherapy, but many patients develop chemoresistant tumors. Therefore, there is a need to develop new therapeutic agents to overcome chemoresistance. Niclosamide, an anti-parasite agent, has shown potent anti-cancer activities in ovarian cancer and other types of human cancers. This study investigates the potential of repurposing niclosamide as a therapeutic agent.
Meeting Abstract
Oncology
Piotr T. Wysocki, Shizhang Ling, Chunbo Shao, Marietta Tan, David Sidransky, Patrick Ha, Mariana Brait
Article
Oncology
Shizhang Ling, Eleni M. Rettig, Marietta Tan, Xiaofei Chang, Zhiming Wang, Mariana Brait, Justin A. Bishop, Elana J. Fertig, Michael Considine, Michael J. Wick, Patrick K. Ha
INTERNATIONAL JOURNAL OF ONCOLOGY
(2016)
Article
Oncology
Camila Maria da Silva Martinelli, Andre van Helvoort Lengert, Flavio Mavignier Carcano, Eduardo Caetano Albino Silva, Mariana Brait, Luiz Fernando Lopes, Daniel Onofre Vidal
Letter
Oncology
Piotr T. Wysocki, William H. Westra, David Sidransky, Mariana Brait
Article
Cardiac & Cardiovascular Systems
Sayantan Datta, Hae-Seong Nam, Masamichi Hayashi, Leonel Maldonado, Rachel Goldberg, Mariana Brait, David Sidransky, Peter Illei, Alex Baras, Neeraj Vij, Mohammad O. Hogue
RESPIRATORY MEDICINE
(2017)
Article
Oncology
Mariana Brait, Mithu Banerjee, Leonel Maldonado, Akira Ooki, Myriam Loyo, Elisa Guida, Evgeny Izumchenko, Leslie Mangold, Elizabeth Humphreys, Eli Rosenbaum, Alan Partin, David Sidransky, Mohammad Obaidul Hoque
Article
Oncology
Leonel Maldonado, Mariana Brait, Evgeny Izumchenko, Shahnaz Begum, Aditi Chatterjee, Tanusree Sen, Myriam Loyo, Alvaro Barbosa, Maria Luana Poeta, Eugene Makarev, Alex Zhavoronkov, Vito M. Fazio, Roberto Angioli, Carla Rabitti, Mate Ongenaert, Wim Van Criekinge, Maartje G. Noordhuis, Pauline de Graeff, G. Bea A. Wismann, Ate G. J. van der Zee, Mohammad O. Hoque
Review
Oncology
Yasmine Ghantous, Juliana L. Schussel, Mariana Brait
CURRENT OPINION IN ONCOLOGY
(2018)
Review
Medical Laboratory Technology
Alessandro Leal, David Sidransky, Mariana Brait
CLINICAL CHEMISTRY
(2020)
Article
Oncology
Sakibul Huq, Joshua Casaos, Riccardo Serra, Michael Peters, Yuanxuan Xia, Andy S. Ding, Jeff Ehresman, Jayanidhi N. Kedda, Manuel Morales, Noah L. Gorelick, Tianna Zhao, Wataru Ishida, Alexander Perdomo-Pantoja, Arba Cecia, Chenchen Ji, Ian Suk, David Sidransky, Mariana Brait, Henry Brem, Nicolas Skuli, Betty Tyler
MOLECULAR CANCER THERAPEUTICS
(2020)
Article
Biochemistry & Molecular Biology
Masamichi Hayashi, Elisa Guida, Yoshikuni Inokawa, Rachel Goldberg, Leonardo O. Reis, Akira Ooki, Manohar Pilli, Pritam Sadhukhan, Juhyung Woo, Woonyoung Choi, Evgeny Izumchenko, Leonel Maldonado Gonzalez, Luigi Marchionni, Alex Zhavoronkov, Mariana Brait, Trinity Bivalacqua, Alexander Baras, George J. Netto, Wayne Koch, Anju Singh, Mohammad O. Hoque
Article
Oncology
Yasmin Ghantous, Aysar Nashef, David Sidransky, Murad Abdelraziq, Kutaiba Alkeesh, Shareef Araidy, Wayne Koch, Mariana Brait, Imad Abu El-Naaj
Summary: This study retrospectively assessed the prognostic and clinical implications of the eighth edition of the TNM staging system in oral cancer treatment. The results demonstrate that incorporating depth of invasion and extranodal extension into staging can provide more accurate prognostic evaluation for patients and determine the need for adjuvant therapy.
Article
Oncology
Akira Ooki, Zahra Maleki, Jun-Chieh J. Tsay, Chandra Goparaju, Mariana Brait, Nitesh Turaga, Hae-Seong Nam, William N. Rom, Harvey I. Pass, David Sidransky, Rafael Guerrero-Preston, Mohammad Obaidul Hoque
CLINICAL CANCER RESEARCH
(2017)
Meeting Abstract
Oncology
Adrian D. Schubert, Evgeny Izumchenko, Piotr T. Wysocki, David Sidransky, Mariana Brait
Article
Oncology
Mariana Brait, Evgeny Izumchenko, Luciane T. Kagohara, Samuel Long, Piotr T. Wysocki, Brian Faherty, Elana J. Fertig, Tin Oo Khor, Elizabeth Bruckheimer, Gilson Baia, Daniel Ciznadija, Ido Sloma, Ido Ben-Zvi, Keren Paz, David Sidransky
BRITISH JOURNAL OF CANCER
(2017)